Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 04 May 2018 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2018 Status changed from not yet recruiting to recruiting.
- 31 Jan 2018 Planned initiation date changed from 1 Feb 2018 to 6 Feb 2018.